FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma By Ogkologos - April 1, 2026 92 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CA209-8UT (SWOG 1826) Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer January 12, 2022 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... October 15, 2021 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma June 11, 2024 Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 Load more HOT NEWS Cannabis, cannabinoids and cancer – the evidence so far EMA Recommends Extension of Therapeutic Indications for Acalabrutinib Groom Uses Wedding To Ask Stepdaughters If He Can Adopt Them EMA Recommends Extension of Therapeutic Indications for Ibrutinib
